Works Cited

1. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 2010;62(6):1576-1582.

2. Centers for Disease Control and Prevention. National Ambulatory Medical Care Survey: 2013 State and National Summary Tables. Available at https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2013_namcs_web_tables.pdf. Last accessed April 6, 2017.

3. Centers for Disease Control and Prevention. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation—United States, 2010–2012. MMWR. 2013;62(44):869-873.

4. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Rheumatoid Arthritis. Washington, DC: National Institutes of Health, U.S. Department of Health and Human Services; 2009.

5. Yelin E, Cisternas M, Foreman A, Pasta D, Murphy L, Helmick CG. National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions: United States, 2003. MMWR. 2007;56(1):4-7.

6. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR (eds). Kelley's Textbook of Rheumatology. 9th ed. Philadelphia, PA: Elsevier/Saunders; 2013: 1059-1069.

7. Dunlop DD, Lyons JS, Manheim LM, Song J, Chang RW. Arthritis and heart disease as risk factors for major depression: the role of functional limitation. Medical Care. 2004;42(6):502-511.

8. Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis. 2005;64(11):1595-1601.

9. Rindflesich JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2005;72(6):1037-1047.

10. Goldring SR. A 55-year-old woman with rheumatoid arthritis. JAMA. 2000;283(4):524-531.

11. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581.

12. O'Dell JR. Rheumatoid arthritis. In: Goldman L, Schafer AI (eds). Goldman-Cecil Medicine. 25th ed. Philadelphia, PA: Saunders Elsevier; 2015.

13. Smith HR, Brown A. Rheumatoid Arthritis. Available at http://emedicine.medscape.com/article/331715-overview. Last accessed April 6, 2017.

14. Pincus T, Sokka T. Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin N Am. 2009;35(4):731-734.

15. British Columbia Medical Association. Rheumatoid Arthritis: Diagnosis, Management, and Monitoring. Available at http://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/rheumatoid-arthritis. Last accessed April 6, 2017.

16. Andersson ML, Svensson B, Petersson IF, et al. Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2013;14:229.

17. Crescendo Bioscience. What is Vectra DA? Available at https://vectrada.com/patients/. Last accessed April 6, 2017.

18. Curtis JR, van der Helm-van Mil AH, Knevel R, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2012;64(12):1794-1803.

19. Vectra DA. Available at https://vectrada.com/. Last accessed April 6, 2017.

20. Lozada CJ, Culpepper SS. Osteoarthritis Workup. Available at http://emedicine.medscape.com/article/330487-workup#c11. Last accessed April 6, 2017.

21. McGonagle D, Tan AL. What magnetic resonance imaging has told us about the pathogenesis of rheumatoid arthritis: the first 50 years. Arthritis Res Ther. 2008;10(5):222.

22. Fujikawa K, Kawakami A, Tamai M, et al. High serum cartilage oligomeric matrix protein determines the subset of patients with early-stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion. J Rheumatol. 2009;36(6):1126-1129.

23. García-Arias M, Pascual-Salcedo D, Ramiro S, et al. Calprotectin in rheumatoid arthritis: association with disease activity in a cross-sectional and a longitudinal cohort. Mol Diagn Ther. 2013;17(1):49-56.

24. Goodman A. Novel Biomarkers Improve Diagnosis in Early RA. Available at http://www.medscape.com/viewarticle/806614. Last accessed April 6, 2017.

25. De Winter L, Hansen W, Geusens P, et al. New autoantibodies as biomarkers for early and seronegative rheumatoid arthritis.Ann Rheum Dis. 2013;72(Suppl 3):114.

26. De Winter LM, Hansen WL, van Steenbergen HW, et al. Autoantibodies to two novel peptides in seronegative and early rheumatoid arthritis. Rheumatology (Oxford). 2016;55(8):1431-1436.

27. O'Dell JR. Clinical features of rheumatoid arthritis. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR (eds). Kelley's Textbook of Rheumatology. 9th ed. Philadelphia, PA: Elsevier/Saunders; 2013: 1109-1136.

28. Akil M, Amos RS. ABC of rheumatology: rheumatoid arthritis. I: clinical features and diagnosis. BMJ. 1995;310(6979):587-590.

29. Venables PJW, Maini RN. Diagnosis and Differential Diagnosis of Rheumatoid Arthritis. Available at http://www.uptodate.com/contents/diagnosis-and-differential-diagnosis-of-rheumatoid-arthritis. Last accessed April 6, 2017.

30. American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum. 2007;57(2):193-202.

31. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35(5):498-502.

32. Smolen JS, Landewé R, Bijilsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.: 2016 update. Ann Rheum Dis. 2017;0:1-18.

33. Jurgens MS, Welsing PM, Jacobs JW. Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S56-63.

34. Boers M. Rheumatoid arthritis: treatment of early disease. Rheum Dis Clin North Am. 2001;27(2):405-414.

35. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2016;68(1):1-26.

36. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007;146(6):406-415.

37. Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med. 1999;131(10):768-774.

38. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350(21):2167-79.

39. van Eijk IC, Nielen MM, van der Horst-Bruinsma I, et al. Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. Rheumatology (Oxford). 2012;51(4):686-694.

40. LexiComp Online. Available at http://online.lexi.com. Last accessed April 6, 2017.

41. American College of Rheumatology. Rheumatoid Arthritis: How is Rheumatoid Arthritis Treated? Available at http://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Rheumatoid-Arthritis. Last accessed April 6, 2017.

42. Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum. 2001;44(9):1984-1992.

43. Singer O, Gibofsky A. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011? Curr Opin Rheumatol. 2011;23(3):288-292.

44. O'Dell JR, Haire CE, Erickson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996;334(20):1287-1291.

45. Nuki G, Breshnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(11):2838-2846.

46. Moreland LW. Biologic therapies on the horizon for rheumatoid arthritis. J Clin Rheumatol. 2004;10(suppl):S32-S39.

47. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586-1593.

48. Lipsky PE, Van der Heijde D, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343(22):1594-1602.

49. St. Clair EW, van der Heijde FM, Smolen JS, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432-3443.

50. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35-45.

51. Goel N, Stephens S. Certolizumab pegol. MAbs. 2010;2(2):137-147.

52. Kay J, Fleischmann R, Keystone E, et al. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2015;74(3):538-546.

53. Kay J, Fleischmann R, Keystone E, et al. Five-year safety data from 5 clinical trials of subcutaneous golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2016;43(12):2120-2130.

54. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane review. Cochrane Database Syst Rev. 2011;2:CD008794.

55. American College of Rheumatology. Rituximab (Rituxan and MabThera). Available at https://www.rheumatology.org/Practice/Clinical/Patients/Medications/Rituximab_%28Rituxan_and_MabThera%29/. Last accessed April 6, 2017.

56. Pyrpasopoulou A, Douma S, Triantafyllou A, et al. Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers. Mol Diagn Ther. 2010;14(1):43-48.

57. American College of Rheumatology. Tocilizumab. Available at https://www.rheumatology.org/Practice/Clinical/Patients/Medications/Tocilizumab_%28Actemra%29/. Last accessed April 6, 2017.

58. Saito S, Kaneko Y, Izumi K, Takeuichi T. Utility of dose frequency adjustment in tocilizumab administration for rheumatoid arthritis. J Rheumatol. 2017;[Epub ahead of print].

59. Kubota N, Ito M, Sakauichi M, Kobayashi K. Rheumatoid neutrophilic dermatitis in a patient taking tocilizumab for treatment of rheumatoid arthritis. J Dermatol. 2017;[Epub ahead of print].

60. National Institute for Health and Care Excellence (NICE). Tocilizumab For The Treatment of Rheumatoid Arthritis. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2012.

61. U.S. Food and Drug Administration. [Archive]. FDA Approves Xeljanz for Rheumatoid Arthritis. Available at https://wayback.archive-it.org/7993/20161022200148/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.htm. Last accessed April 6, 2017.

62. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-2285.

63. Wolfe F. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large U.S. observational study. Arthritis Rheum. 2007;56(9):2886-2895.

64. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):529-535.

65. Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;[Epub ahead of print].

66. Welch B. Adalimumab (Humira) for the treatment of rheumatoid arthritis. Am Fam Phys. 2008;78(12):1406-1408.

67. Kirwan JR, for the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med. 1995;333(3):142-146.

68. American College of Rheumatology. Glucocorticoid-Induced Osteoporosis. Available at https://www.rheumatology.org/Practice/Clinical/Patients/Diseases_And_Conditions/Glucocorticoid-Induced_Osteoporosis/. Last accessed April 6, 2017.

69. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects. Ann Intern Med. 2002;136(1):1-12.

70. National Institutes of Health Consensus Development Panel on Total Knee Replacement. Consensus Statement on Total Knee Replacement: Final Statement. Rockville, MD: U.S. Department of Health and Human Services; 2004.

71. Rasul AT Jr, Wright J. Total Joint Replacement Rehabilitation. Available at http://emedicine.medscape.com/article/320061-overview. Last accessed April 6, 2017.

72. Wells G, Li T, Maxwell L, MacLean R, Tugwell P. Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. J Rheumatol. 2007;34(2):280-289.

73. Rao JK, Mihaliak K, Kroenke K, Bradley J, Tierney WM, Weinberger M. Use of complementary therapies for arthritis among patients of rheumatologists. Ann Intern Med. 1999;131(6):409-416.

74. Tindle HA, Davis RB, Phillips RS, Eisenberg DM. Trends in use of complementary and alternative medicine by U.S. adults: 1997–2002. Altern Ther Health Med. 2005;11(1):42-49.

75. Robinson A, McGrail MR. Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies. Complement Ther Med. 2004;12(2-3):90-98.

76. Ernst E, Posadzki P. Complementary and alternative medicine for rheumatoid arthritis and osteoarthritis: an overview of systematic reviews. Curr Pain Headache Rep. 2011;15(6):431-437.

77. Clarke TC, Nahin RL, Barnes PM, Stussman BJ. Use of Complementary Health Approaches for Musculoskeletal Pain Disorders Among Adults: United States, 2012. National Health Statistics Reports, No. 98. Hyattsville, MD: National Center for Health Statistics; 2016.

78. Efthimiou P, Kukar M, Mackenzie CR. Complementary and alternative medicine in rheumatoid arthritis: no longer the last resort! HSS J. 2010;6(1):108-111.

79. Tamhane A, McGwin G Jr, Redden DT, et al. Complementary and alternative medicine use in African Americans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(2):180-189.

80. Zhao S, Otieno F, Akpan A, Moots RJ. Complementary and alternative medicine use in rheumatoid arthritis: considerations for the pharmacological management of elderly patients. Drugs Aging. 2017;34(4):255-264.

81. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report. 2008;(12):1-23.

82. National Center for Complementary and Alternative Medicine. Rheumatoid Arthritis: In Depth: Other Types of Complementary Health Approaches Studies for Rheumatoid Arthritis. Available at https://nccih.nih.gov/health/RA/getthefacts.htm#hed1. Last accessed April 6, 2017.

83. National Institutes of Health. Handout on Health: Rheumatoid Arthritis. Available at http://www.niams.nih.gov/health_info/Rheumatic_Disease. Last accessed April 6, 2017.

84. Szarc Vel Szic K, Ndlovu MN, Haegeman G, Vanden Berghe W. Nature or nurture: let food be your epigenetic medicine in chronic inflammatory disorders. Biochem Pharmacol. 2010;80(12):1816-1832.

85. James M, Proudman S, Cleland L. Fish oil and rheumatoid arthritis: past, present and future. Proc Nutr Soc. 2010;69(3):316-323.

86. Proudman SM, James MJ, Spargo LD, et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis. 2015;74(1):89-95.

87. Arthritis Foundation. The Benefits of Omega-3 Fatty Acids for Arthritis. Available at http://blog.arthritis.org/living-with-arthritis/omega-3-fatty-acids-arthritis/. Last accessed April 6, 2017.

88. Ierna M, Kerr A, Scales H, Berge K, Griinari M. Supplementation of diet with krill oil protects against experimental rheumatoid arthritis. BMC Musculoskelet Disord. 2010;11:136.

89. Watson PD, Joy PS, Nkonde C, Hessen SE, Karalis DG. Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel versus aspirin + clopidogrel in patients with cardiovascular disease. Am J Cardiol. 2009;104(8):1052-1054.

90. American College of Rheumatology. Exercise and Arthritis. Available at http://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Living-Well-with-Rheumatic-Disease/Exercise-and-Arthritis. Last accessed April 6, 2017.

91. Ottawa Panel. Ottawa Panel evidence-based clinical practice guidelines for therapeutic exercises in the management of rheumatoid arthritis in adults. Phys Ther. 2004;84(10):934-972.

92. Vliet Vlieland TPM. Are static resting wrist splints beneficial in early RA? Nat Clin Pract Rheumatol. 2009;5(3):124-125.

93. Rao S, Baumhauer JF, Tome J, Nawoczenski DA. Orthoses alter in vivo segmental foot kinematics during walking in patients with midfoot arthritis. Arch Phys Med Rehabil. 2010;91(4):608-614.

94. Adams J, Burridge J, Mullee M, Hammond A, Cooper C. The clinical effectiveness of static resting splints in early rheumatoid arthritis: a randomized controlled trial. Rheumatol. 2008;47(10):1548-1553.

95. Veehof MM, Taal E, Willems MJ, van de Laar MAFJ. Determinants of the use of wrist working splints in rheumatoid arthritis. Arthritis Care Res. 2008;59(4):531-536.

96. Ramsey L, Winder RJ, McVeigh JG. The effectiveness of working wrist splints in adults with rheumatoid arthritis: a mixed methods systematic review. J Rehabil Med. 2014;46(6):481-492.

97. van der Giesen FJ, van Lankveld WJ, Kremers-Selten C, et al. Effectiveness of two finger splints for swan neck deformity in patients with rheumatoid arthritis: a randomized, crossover trial. Arthritis Care Res. 2009;61(8):1025-1031.

98. Straub RH, Kalden JR. Stress of different types increases the proinflammatory load in rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):114-115.

99. Davis MC, Zautra AJ, Younger J, Motivala SJ, Attrep J, Irwin MR. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immun. 2008;22(1):24-32.

100. Zautra AJ, Parrish BP, Van Puymbroeck CM, et al. Depression history, stress, and pain in rheumatoid arthritis patients. J Behav Med. 2007;30(3):187-197.

101. Pradhan EK, Baumgarten M, Langenberg P, et al. Effect of mindfulness-based stress reduction in rheumatoid arthritis patients. Arthritis Care Res. 2007;57(7):1134-1142.

102. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62(8):722-727.

103. Hara KS, Ballard DJ, Ilstrup DM, Connolly DC, Vollertsen RS. Rheumatoid pericarditis: clinical features and survival. Medicine (Baltimore). 1990;69(2):81-91.

104. Kremers HM, Crowson CS, Therneau TM, et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum. 2008;58(8):2268-2274.

105. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52(2):402-411.

106. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107(9):1303-1307.

107. del Rincón ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44(12):2737-2745.

108. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690-1697.

109. Balbir-Gurman A, Yigla M, Nahir AM, Braun-Moscovici Y. Rheumatoid pleural effusion. Semin Arthritis Rheum. 2006;35(6):368-378.

110. Helmers R, Galvin J, Hunninghake GW. Pulmonary manifestations associated with rheumatoid arthritis. Chest. 1991;100(1):235-238.

111. Jurik AG, Davidsen D, Graudal H. Prevalence of pulmonary involvement in rheumatoid arthritis and its relationship to some characteristics of the patients: a radiological and clinical study. Scand J Rheumatol. 1982;11(4):217-224.

112. Lee H-K, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127(6):2019-2027.

113. Suzuki A, Ohosone Y, Obana M, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol. 1994;21(1):33-36.

114. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997;156(pt1):528-535.

115. Saag KG, Kolluri S, Koehnke RK, et al. Rheumatoid arthritis lung disease: determinants of radiographic and physiologic abnormalities. Arthritis Rheum. 1996;39(10):1711-1719.

116. Androudi S, Dastiridou A, Symeonidis C, et al. Retinal vasculitis in rheumatic diseases: an unseen burden. Clin Rheumatol. 2013;32(1):7-13.

117. Genta MS, Genta RM, Gabay C. Systemic rheumatoid vasculitis: a review. Semin Arthritis Rheum. 2006;36(2):88-98.

118. Melsom RD, Horsfall AC, Schrieber L, Charles P, Maini RN. Anti-C1q affinity isolated circulating immune complexes correlate with extra-articular rheumatoid disease. Rheumatol Int. 1986;6(5):227-231.

119. Scott DG, Bacon PA, Allen C, Elson CJ, Wallington T. IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: comparative and serial studies during cytotoxic therapy. Clin Exp Immunol. 1981;43(1):54-63.

120. Guillevin L, Dorner T. Vasculitis: mechanisms involved and clinical manifestations. Arthritis Res Ther. 2007;9(Suppl 2):S9.

121. Young S. Ocular involvement in connective tissue disorders. Curr Allergy Asthma Rep. 2005;5(4):323-326.

122. Smith JR, Mackensen F, Rosenbaum JT. Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat Clin Pract Rheumatol. 2007;3(4):219-226.

123. Michels ML, Cobo LM, Caldwell DS, Rice JR, Haynes BF. Rheumatoid arthritis and sterile corneal ulceration: analysis of tissue immune effector cells and ocular epithelial antigens using monoclonal antibodies. Arthritis Rheum. 1984;27(6):606-614.

124. Fujita M, Igarashi T, Kurai T, Sakane M, Yoshino S, Takahashi H. Correlation between dry eye and rheumatoid arthritis activity. Am J Ophthalmol. 2005;140(5):808-813.

125. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis: effects of systemic immunosuppression. Ophthalmology. 1984;91(91):1253-1263.

126. Fox RI. Sjögren's syndrome. Lancet. 2005;366(9482):321-331.

127. Matsuo T, Kono R, Matsuo N, et al. Incidence of ocular complications in rheumatoid arthritis and the relation of keratoconjunctivitis sicca with its systemic activity. Scand J Rheumatol. 1997;26(2):113-116.

128. Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol. 2005;1(1):47-54.

129. Compston JE, Vedi S, Croucher PI, Garrahan NJ, O'Sullivan MM. Bone turnover in non-steroid treated rheumatoid arthritis.Ann Rheum Dis. 1994;53(3):163-166.

130. Roldan JF, Del Rincon I, Escalante A. Loss of cortical bone from the metacarpal diaphysis in patients with rheumatoid arthritis: independent effects of systemic inflammation and glucocorticoids. J Rheumatol. 2006;33(3):508-516.

131. Strand V, Kavanaugh AF. The role of interleukin-1 in bone resorption in rheumatoid arthritis. Rheumatology. 2004;43(Suppl 3):iii10-iii16.

132. Bowman SJ. Hematological manifestations of rheumatoid arthritis. Scand J Rheumatol. 2002;31(5):251-259.

133. Wilson A, Yu H-T, Goodnough LT, Nissenson AR. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med. 2004;116(suppl7A):50S-57S.

134. Vreugdenhil G, Lowenberg B, Van Eijk HG, Swaak AJ. Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis. Eur J Clin Invest. 1992;22(7):488-493.

135. Jongen-Lavrencic M, Peeters HR, Wognum A, Vreugdenhil G, Breedveld FC, Swaak AJ. Elevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic disease. J Rheumatol. 1997;24(8):1504-1509.

136. Cronstein BN. Interleukin-6: a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(suppl1):S11-S15.

137. Farr M, Scott DL, Constable TJ, Hawker RJ, Hawkins CF, Stuart J. Thrombocytosis of active rheumatoid disease. Ann Rheum Dis. 1983;42(5):545-549.

138. Ayvaz OC, yavasoglu I, Kadikoylu G, Bozkurt G, Bolaman Z. Thrombocytosis in rheumatoid arthritis: JAK2V617F-positive essential thrombocythemia. Rheumatol Int. 2012;32(1):269-271.

139. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692-701.

140. Upile T, Jerjes W, Sipaul F, Singh S, Hopper C, Wright A, Sandison A. Rheumatoid nodule of the thyrohyoid membrane: a case report. J Med Case Reports. 2007;1:123.

141. Palmer DG, Hogg N, Highton J, et al. Macrophage migration and maturation within rheumatoid nodules. Arthritis Rheum. 1987;30(7):728-736.

142. Edwards JCW, Wilkinson LS, Pitsillides AA. Palisading cells of rheumatoid nodules: comparison with synovial intimal cells.Ann Rheum Dis. 1993;52(11):801-805.

143. Joaquim AF, Appenzeller S. Cervical spine involvement in rheumatoid arthritis – a systematic review. Autoimmun Rev. 2014;13(12):1195-1202.

144. Collins DN, Barnes CL, FitzRandolph RL. Cervical spine instability in rheumatoid patients having total hip or knee arthroplasty. Clin Orthop. 1991;272:127-135.

145. Agarwal AK, Peppelman WC, Kraus DR, et al. Recurrence of cervical spine instability in rheumatoid arthritis following previous fusion: can disease progression be prevented by early surgery? J Rheumatol. 1992;19(9):1364-1370.

146. Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS. Assessing remission in clinical practice. Rheumatology (Oxford). 2007;46(6):975-979.

147. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum. 1996;39(1):34-40.

148. Janta I, Naredo E, Martínez-Estupiñán L, et al. Patient self-assessment and physician's assessment of rheumatoid arthritis activity: which is more realistic in remission status? A comparison with ultrasonography. Rheumatology (Oxford). 2013;52(12):2243-2250.

149. Lee DM, Weinblatt ME. Rheumatoid arthritis. The Lancet. 2001;358(9285):903-911.

150. Agca R, Heslinga SC, Rollesfstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17-28.

151. U.S. Census Bureau. Selected Social Characteristics in the United States: 2015. Available at https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml. Last accessed April 6, 2017.

152. Karliner L, Napoles-Springer AM, Schillinger D, Bibbins-Domingo K, Pérez-Stable EJ. Identification of limited English proficient patients in clinical care. J Gen Intern Med. 2008;23(10):1555-1560.

153. Sevilla Matir J, Willis DR. Using bilingual staff members as interpreters. Fam Pract Manage. 2004;11(7):34-36.

154. Ngo-Metzger Q, Massagli MP, Clarridge BR, et al. Linguistic and cultural barriers to care: perspectives of Chinese and Vietnamese immigrants. J Gen Intern Med. 2003;18(1):44-52.

155. Flores G. Language barriers to health care in the United States. N Engl J Med. 2006;355(3):229-231.

156. Flores G. The impact of medical interpreter services on the quality of health care: a systematic review. Med Care Res Rev. 2005;62(3):255-299.

157. Karliner L, Jacobs EA, Chen AH, Mutha S. Do professional interpreters improve clinical care for patients with limited English proficiency? A systematic review of the literature. Health Serv Res. 2007;42(2):727-754.

158. Gias C. Quality of life. In: Lubkin IM, Larsen PD (eds). Chronic Illness: Impact and Interventions. 9th ed. Boston, MA: Jones and Bartlett Publishers; 2016: 149-176.

159. Larsen PD. Chronicity. In: Lubkin IM, Larsen PD (eds). Chronic Illness: Impact and Interventions. 9th ed. Boston, MA: Jones and Bartlett Publishers; 2016: 3-22.

160. Sidell NL. Adult adjustment to chronic illness: a review of the literature. Health Soc Work. 1997;22(1):5-11.

161. Livneh Hanoch, Antonak RF. Psychosocial adaptation to chronic illness and disability: a primer for counselors. J Couns Dev. 2005;83(1):12-20.

162. Rando TA. The increasing prevalence of complicated mourning: the onslaught is just beginning. Omega. 1992;26(1):43-59.

163. Olshansky S. Chronic sorrow: a response to having a mentally defective child. Soc Casework. 1962;43:190-193.

164. Roberts CS, Piper L, Denny J, Cuddeback G. A support group intervention to facilitate young adults' adjustment to cancer.Health Soc Work. 1997;22(2):133-141.

165. Foley DP. Eleven interpretations of personal suffering. J Relig Health. 1988;27(4):321-328.

166. Wolfe F, Michaud K. Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity. Arthritis Care Res. 2009;61(5):667-673.

167. Margaretten M, Barton J, Julian L, et al. Socioeconomic determinants of disability and depression in patients with rheumatoid arthritis. Arthritis Care Res. 2011;63(2):240-246.

168. Sleath B, Chewning B, de Vellis BM, et al. Communication about depression during rheumatoid arthritis patient visits. Arthritis Care Res. 2008;59(2):186-191.

169. Sleath B, Rubin RH. Gender, ethnicity, and physician-patient communication about depression and anxiety in primary care.Patient Educ Couns. 2002;48:243-252.

170. Nicholson NR Jr. Social isolation. In: Lubkin IM, Larsen PD (eds). Chronic Illness: Impact and Interventions. 9th ed. Boston, MA: Jones and Bartlett Publishers; 2016: 101-126.

171. Patterson JM, Garwick AW. The impact of chronic illness on families: a family perspective. Ann Behav Med. 1994;16(2):131-142.

172. Boice MM. Chronic illness in adolescence. Adolescence. 1998;33(132):927-939.

173. Clark HB, Ichinose CK, Meseck-Bushey S, et al. Peer support group for adolescents with chronic illness. Child Health Care. 2002;21(4):233-238.

174. Eccleston C, Wastell S, Crombez G, Jordan A. Adolescent social development and chronic pain. Eur J Pain. 2008;12(6):765-774.

175. Larsen PD. Impact of Chronic Illness on the Patient and Family. In: Lubkin IM, Larsen PD (eds). Chronic Illness: Impact and Interventions. 9th ed. Boston, MA: Jones and Bartlett Publishers; 2016: 22-31.

176. Erikson EH. Reflections on Dr. Borg's life cycle. In: Erikson EH (ed). Adulthood. New York, NY: Norton; 1978: 1-31.

Evidence-Based Practice Recommendations Citations

1. Jacobson JA, Roberts CC, Bencardino JT, et al. ACR Appropriateness Criteria: Chronic Extremity Joint Pain, Suspected Inflammatory Arthritis. Reston, VA: American College of Radiology; 2016. Summary retrieved from National Guideline Clearinghouse at https://guidelines.gov/summaries/summary/50494. Last accessed April 12, 2017.

2. Medical Services Commission. Rheumatoid Arthritis: Diagnosis, Management and Monitoring. Victoria: British Columbia Medical Services Commission; 2012. Summary retrieved from National Guideline Clearinghouse at https://guidelines.gov/summaries/summary/39244. Last accessed April 12, 2017.

3. National Institute for Health and Clinical Excellence. Tocilizumab for the Treatment of Rheumatoid Arthritis. London: National Institute for Health and Clinical Excellence; 2012. Summary retrieved from National Guideline Clearinghouse at https://guidelines.gov/summaries/summary/36890. Last accessed April 12, 2017.



Privacy Policy
Copyright © 2017 CE Resource, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.